Current guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Asia Pacific Association for the Study of the Liver (APASL) suggest the administration of peg-IFN-α for 12 months to subjects with elevated HDV RNA and ALT serum levels [92,93]; similarly, the guidelines of the European Association for the Study of the Liver (EASL) recommend administering peg-IFN-α at least for 48 weeks to HDV-CH patients with compensated liver disease [94]. This evidence concerns the gene GPT and liver disorder.